Patient access schemes for high-cost cancer medicines: Good in theory, difficult in practice
created by the pharmaceutical industry to allow access to expensive cancer drugsācan be fraught with administrative problems, meaning that money does not reach the parts of the UK National Health Service that it should, ...
